Valye reports for unlimited access

LIXTE Biotechnology Holdings, Inc. develops cancer therapies centered on LB-100, a small molecule inhibitor of PP2A, which enhances the efficacy of chemotherapy, immunotherapy, and radiation treatments. The company also holds a majority stake in Liora Technologies Europe Ltd., which develops advanced proton therapy systems. LIXTE's clinical programs include trials for ovarian clear cell carcinoma, metastatic colon cancer, and soft tissue sarcoma, conducted in collaboration with institutions such as MD Anderson Cancer Center, the Netherlands Cancer Institute, and the Spanish Sarcoma Group. The company operates with a lean structure, funding development stages through capital raises and partnerships.

Non-Invasive Monitoring Systems, Inc. (NIMS) was incorporated in Florida in 1980 and historically focused on non-invasive, motorized whole body periodic acceleration platforms designed to temporarily increase local circulation and relieve minor aches and pains. The company ceased operations in May 2019 and is currently classified as a shell company. It holds no inventory or products for sale. Financially, NIMS has sustained recurring losses and an accumulated deficit, with liquidity ratios indicating significant short-term financial constraints. The company has engaged in convertible note financing and merger-related agreements in 2026. Corporate governance is limited, lacking independent audit and compensation committees. The common stock is traded as a penny stock on OTC Pink, which may affect liquidity and marketability.

Dragonfly Energy Holdings Corp. is a manufacturer of lithium iron phosphate (LFP) deep cycle batteries and integrated power system components. The company’s products serve multiple end markets including recreational vehicles, marine vessels, industrial applications, and heavy-duty trucking. Dragonfly’s LFP batteries offer environmental and safety advantages over traditional lead-acid batteries, including longer lifespan, non-toxicity, and improved performance in cold temperatures. The company has proprietary dry-electrode manufacturing technology and is developing solid-state battery technology to enhance safety and cost efficiency. Dragonfly has shifted its growth strategy toward OEM and fleet partnerships, expanding product integration in factory-installed applications and commercial deployments. The company operates a large manufacturing facility in Reno, Nevada, supporting scalable production and assembly of battery packs. Its product portfolio includes battery packs with integrated management systems, heating capabilities, and system-level communication enabled by Dragonfly IntelLigence technology. Dragonfly’s OEM partners include leading RV manufacturers and it is expanding into industrial and heavy-duty trucking markets with solutions aimed at reducing diesel fuel costs and complying with anti-idling regulations [S1][S2].

Professional Diversity Network, Inc. operates in the recruitment and diversity network sector, providing services such as membership fees, recruitment services, contracted software development, and consumer advertising and marketing solutions. The company has integrated AI technologies into its TalentAlly recruitment platform through a $1.3 million investment in AI Geometric Ltd. It also operates the RemoteMore business segment, which has shown growth alongside narrowing losses. The company manages cybersecurity risks through a comprehensive program led by its CTO and overseen by the Audit Committee. However, liquidity ratios as of mid-2026 indicate some constraints, with a current ratio below 1. The company is also facing a Nasdaq compliance challenge as of early 2026.

Agape ATP Corporation is a Nevada-based holding company with subsidiaries primarily in Malaysia and Hong Kong, engaged in the health and wellness industry. Its core business includes supplying health supplements and wellness products designed to improve cellular health and overall wellbeing. The company operates a direct selling network marketing model, leveraging a large distributor and member base in Malaysia. It also pursues diversification into renewable energy solutions and digital wellness platforms targeting the ASEAN market. The company emphasizes distributor training, product quality control, and regulatory compliance in Malaysia.

Our Bond, Inc. provides cloud-based video surveillance and personal security technology solutions, complemented by physical security services such as drone operations, security guards, and executive protection. The company's technology requires ongoing development and maintenance to remain compatible with major ecosystem platforms. It handles sensitive biometric and personally identifiable information, subjecting it to complex and evolving privacy regulations domestically and internationally. The business model relies on third-party hardware and software suppliers and faces operational risks from regulatory compliance and data security challenges.

Leatt Corp is a Nevada-incorporated company specializing in the design, development, marketing, and distribution of personal protective equipment (PPE) for motor sports and leisure activities such as motorcycling, bicycling, snowmobiling, and ATV riding. The company’s core product is the Leatt-Brace®, a patented neck protection system designed to prevent cervical spine injuries. Leatt also offers a broad range of helmets, body protection gear, goggles, and sunglasses under its brand, incorporating proprietary safety technologies. Manufacturing is outsourced primarily to China, with growing capacity in Thailand, Cambodia, and Bangladesh. The company sells its products globally through approximately 61 distributors and 6 e-commerce partners, with direct distribution in the US and South Africa. Research and development is centralized in Cape Town, South Africa. The company holds multiple international safety certifications for its products and faces risks related to global economic conditions, trade policies, product liability, and currency fluctuations [S1][S2].

Allarity Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company specializing in oncology therapeutics. Its lead drug candidate, Stenoparib, is undergoing clinical trials targeting lung cancer, colorectal cancer, and ovarian cancer. The company is also developing its Drug Response Predictor (DRP) platform to support precision oncology, particularly in breast cancer. Financing activities include equity and debt instruments to support clinical development and regulatory approval efforts. The company consolidates a variable interest entity, ALLR Sponsor LLC, which introduces additional operational and financial considerations.

Clene Inc. pioneers the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics (CSN®) composed of transition element nanocrystals with unique catalytic activities. These nanocrystals catalyze beneficial metabolic and energetic cellular reactions, targeting diseases with high unmet medical needs, particularly neurodegenerative disorders such as ALS, MS, and Parkinson's disease. The company’s proprietary electro-crystal-chemistry platform produces highly active, non-toxic nanocrystals free of chemical surface modifications common in other nanoparticle synthesis methods. Clene’s lead drug candidate, CNM-Au8, is a gold nanocrystal suspension that catalyzes the conversion of NADH to NAD+, enhancing cellular energy production and reducing oxidative stress. The company has completed multiple clinical trials and maintains ongoing open-label extensions and expanded access programs. Additional therapeutic assets include zinc and silver ion-based antiviral and antibacterial agents in early development. Clene also markets dietary supplements through its subsidiary and an exclusive licensee. The company outsources much of its clinical trial management to expert CROs while maintaining oversight. Clene faces typical pharmaceutical development risks including regulatory approval, financing, and competition.

GT Biopharma, Inc. focuses on developing novel immuno-oncology products using its proprietary TriKE® and Dual Targeting TriKE® platforms. These platforms harness the patient's natural killer (NK) cells to target and kill cancer cells by binding to specific tumor antigens such as B7-H3, HER2, CD33, and PDL1. The company’s pipeline includes GTB-3650, a second-generation camelid nanobody TriKE targeting CD33 for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), currently in Phase 1 clinical trials; GTB-5550, targeting B7-H3 on solid tumors, with FDA IND clearance and initial patient dosing in Phase 1 trials; and GTB-7550, targeting CD19 for autoimmune disorders, in preclinical development. The company has exclusive rights to the TriKE platform and collaborates with the University of Minnesota for clinical research. GT Biopharma has not yet generated revenue and has sustained operating losses since inception.

Zapata Quantum, Inc. is a publicly reporting company with recent SEC filings including a 10-K and 10-Q. The company reported no revenue and a net loss in the most recent quarter ending June 30, 2026. Its balance sheet shows modest current assets relative to current liabilities, with a current ratio of 1.23. The company has no reported cash and cash equivalents as of the end of 2025. There is no disclosed material litigation or legal proceedings. Risk factors disclosures are minimal due to smaller reporting company status. Public news coverage provides limited direct information about Zapata Quantum's business operations or market positioning.

1847 Holdings LLC operates as an acquisition holding company that acquires and manages a portfolio of small businesses, defined as those with enterprise values below $50 million, primarily in North America. The company focuses on industries with long-term growth potential and targets businesses with positive and stable earnings and cash flows. Its strategy involves acquiring controlling interests, growing businesses organically and through add-on acquisitions, and improving operational efficiencies. The company limits leverage to maintain operational flexibility and avoid stringent lender controls. Capital is raised through debt, equity offerings, and sales of subsidiaries. The company also considers selling businesses based on financial and strategic considerations. Management emphasizes strong relationships with brokers and financial intermediaries to source acquisition opportunities and applies rigorous due diligence and integration processes. The company reported revenue of $1.567 million and a net loss of $6.763 million for Q2 2026, with liquidity challenges noted in recent filings.

Mainz Biomed N.V. develops and markets in-vitro diagnostic tests for early cancer detection. Historically, it offered ColoAlert, a CE-IVD certified colorectal cancer screening test in Europe, combining fecal immunochemical testing with PCR-based genetic marker analysis. The company conducted clinical studies validating mRNA biomarkers combined with FIT for colorectal cancer and advanced adenoma detection, demonstrating high sensitivity and specificity. In 2025, Mainz Biomed acquired exclusive rights to novel mRNA biomarkers and an AI algorithm from Liquid Bioscience for non-invasive pancreatic cancer detection via blood test and is developing PancAlert, a stool-based pancreatic cancer screening test. In early 2026, the company shifted strategic focus to pancreatic cancer detection and post-quantum cybersecurity, ceasing colorectal cancer product development and selling related intellectual property. The company is headquartered in Mainz, Germany, with a small workforce and maintains liquidity to support operations.

Genvor Inc is a biotechnology company focused on developing and commercializing AI-accelerated peptide technologies primarily for sustainable agriculture. The company’s proprietary BioCypher Algorithm integrates computational biology and machine learning to accelerate peptide discovery and optimize commercial viability. Genvor’s peptide portfolio includes antimicrobial peptides for broad-spectrum crop protection, nutritionally enhanced peptides to improve nutrient uptake and yield, crop-enhancing peptides for stress tolerance, and insecticidal peptides for targeted pest control. These peptides are designed to be biodegradable and reduce resistance risks compared to conventional chemical pesticides. The company’s business model emphasizes capital efficiency by leveraging strategic partnerships, licensing agreements, and joint development collaborations with agricultural organizations that provide regulatory expertise and market access. Genvor holds multiple U.S. patents and pending applications covering its peptide technologies and commercial applications, including transgenic corn expressing antifungal peptides. The company is also expanding into the health and wellness market, applying its AI platform to develop consumer peptide solutions. Financially, as of June 30, 2026, Genvor reported current assets of $262,243 against current liabilities of $2,814,195, indicating liquidity challenges, and a net loss of $2,556,468 for the period. The company has engaged in capital raising through convertible promissory notes and warrants to support operations and growth.

Nuvera Communications, Inc. is a communications company focused on providing broadband and video services. Its growth strategy emphasizes expanding its fiber broadband network into new communities, requiring regulatory approvals and significant capital investment. The company operates in a highly competitive environment with competitors ranging from traditional cable and wireless providers to emerging OTT content services. Nuvera receives substantial support from federal and state universal service programs, which form a significant portion of its revenue. The company reported revenues of approximately $17.7 million and a net loss for the first half of 2026. It maintains liquidity with a current ratio of 1.9 but carries significant debt related to its fiber network buildout. Nuvera faces risks from competition, technological changes, regulatory uncertainties, and potential network disruptions [S1][S2].

VerifyMe, Inc. is a company listed on The Nasdaq Capital Market under the ticker VRME. The company provides services in authentication, precision logistics, brand protection, and premium services. It has filed recent SEC reports including a 10-K for fiscal year 2025 and a 10-Q for the quarter ended June 30, 2026, which provide detailed financial and operational disclosures. The company reported revenue of $1.908 million and a net loss of $505,000 for the latest quarter, with liquidity ratios indicating a strong short-term financial position. Risk factors and management discussions are disclosed in the filings with no recent material changes.

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel therapies primarily for cancer treatment. Its lead candidate, IFx-2.0, targets advanced cutaneous melanoma and has received FDA Orphan Drug Designation. The company is conducting a Phase 3 clinical trial for IFx-2.0 and advancing other candidates such as TBS-2025. TuHURA has expanded its pipeline through a merger agreement with Kineta. The company has no current product revenue and finances operations through equity and debt. It reported a net loss of $9.22 million for Q2 2026 and held under $1 million in cash as of June 30, 2026, with a low current ratio indicating liquidity constraints. TuHURA is supported by analyst coverage with positive recommendations and continues to invest heavily in research and development.

Upland Software, Inc. provides a suite of cloud-based software applications designed to support enterprise digital transformation initiatives. Its offerings focus on unlocking critical knowledge, automating content workflows, enhancing customer and employee experiences, and ensuring regulatory compliance. The company serves a broad customer base exceeding 1,100 enterprises. Revenue streams include subscription and support fees for cloud applications, perpetual license sales, and professional services such as implementation and training. The company has actively managed its portfolio by divesting non-core product lines and discontinuing certain non-strategic assets, which has influenced recent revenue trends. Operating expenses encompass sales and marketing, research and development, general administration, and costs related to acquisitions and divestitures. Upland faces challenges related to Nasdaq listing compliance due to share price and market value thresholds.

Silexion Therapeutics Corp is a clinical-stage biotechnology company incorporated in the Cayman Islands, trading on Nasdaq under ticker SLXN. The company is developing SIL204, an RNA interference therapeutic targeting KRAS-driven cancers, including pancreatic and lung cancers. Silexion has reported positive preclinical efficacy data and has advanced SIL204 into Phase 2/3 clinical trials, with regulatory clearance from German authorities. The company has engaged in strategic collaborations, notably with Catalent, to support development and manufacturing. Capital raising activities include warrant exercises and private placements to fund clinical operations. Financial disclosures indicate ongoing net losses and liquidity below 1.0 current ratio as of mid-2026.

Community Bancorp /VT operates primarily through its wholly owned subsidiary, Community National Bank, serving a geographically concentrated market in northeastern and central Vermont. The company’s funding strategy relies mainly on deposit gathering, which provides low-cost funding for loan growth and operations. The loan portfolio is heavily weighted toward real estate-secured loans, exposing the company to local real estate market risks. The company’s financial performance is sensitive to interest rate fluctuations affecting net interest income. Recent financial disclosures show asset base changes with loan growth offset by decreases in federal funds and deposits, reflecting typical seasonal patterns. The company maintains capital ratios above regulatory requirements and continues to pay quarterly dividends. Operational risks include credit risk, liquidity risk, interest rate risk, and cybersecurity risks. Regulatory compliance and changes in banking laws also present ongoing challenges.

Kartoon Studios, Inc. operates as a global content and brand management company focused on children's animated multimedia content. Its business model includes original IP development, third-party production services, media agency operations, and content monetization through licensing and owned distribution platforms. The company owns and produces various popular titles and operates Mainframe Studios, a major animation production studio, and Frederator Networks, a leading animation creator network on YouTube. Distribution spans streaming platforms, linear TV, and subscription and ad-supported VOD services such as Kartoon Channel! and Ameba TV. Revenue sources include production services, licensing, advertising, and merchandising. The company also owns Beacon Media Group, a specialized media and marketing agency serving the toy and family entertainment sectors. Kartoon Studios holds strategic interests in European content provider Your Family Entertainment AG and controls Stan Lee Universe, LLC. The company faces competition from major children's content creators and distributors and operates in a regulatory environment including COPPA compliance and potential trade policy impacts [S1][S2].

Volato Group, Inc. is a publicly traded emerging growth company listed on the NYSE American under the ticker SOAR. The company operates the Vaunt platform, which provides light jet services and has recently enhanced its offerings by adding 13 new aircraft through a partnership with Leviate Air Group. The company has announced a new aircraft leasing program aimed at increasing revenue. Leadership includes CEO Matthew Liotta and a board of five directors with independent members. Volato has resolved prior NYSE noncompliance issues and withdrew its S-1 registration statement in late 2024. The company has also developed patent-pending technology related to cryptocurrency mining. Financially, as of June 30, 2026, Volato reported $152,000 in revenue and a net loss of $2.051 million for the quarter, with a current ratio of 1.11 and no cash on hand. The company has recently raised capital through equity offerings totaling approximately $4 million in mid-2026. The business plan includes pursuing acquisitions and strategic relationships, though a previously planned merger was terminated in June 2026.

Algorhythm Holdings, Inc. operates as an AI technology company focused on its SemiCab platform, an AI-enabled, cloud-based collaborative transportation and logistics software. SemiCab integrates real-time data from various logistics systems and uses AI and machine learning to optimize freight loads and truck utilization, aiming to reduce empty miles and logistics costs while improving asset utilization and sustainability. The company offers managed transportation services in India and a SaaS subscription model called Apex in the US and Europe, targeting shippers, carriers, and third-party logistics providers. Algorhythm sold its prior Singing Machine karaoke consumer products business in August 2025 and now focuses solely on the SemiCab logistics business. The company has made acquisitions, including SMCB in India, to expand its logistics operations. Algorhythm faces a competitive and fragmented transportation services market and seeks to grow its customer base and platform capabilities through ongoing R&D and marketing efforts [S1][S2].

ClearSign Technologies Corp specializes in combustion technology designed to reduce nitrogen oxide (NOx) emissions and improve operational efficiency in industrial and commercial combustion systems. Its core product, the ClearSign Core™ technology, utilizes a patented flame stabilizing structure to achieve low emissions without traditional external pollution control systems. The company targets markets including energy production, refining, petrochemical, and boiler industries, focusing on retrofit and new burner installations. ClearSign operates an asset-light model, partnering with established OEMs such as Zeeco and California Boiler to manufacture and distribute its products. The company also develops flame sensing technology (ClearSign Eye) with potential applications beyond combustion markets. Regulatory recognition and multiple customer installations support its market presence. Financially, ClearSign reported a net loss and negative EPS in Q2 2026 but maintains a strong liquidity position.

URSB Bancorp, Inc. was incorporated in 2025 to serve as the bank holding company for United Roosevelt Savings Bank and its subsidiary following a mutual-to-stock conversion. The company operates primarily through the bank and its investment subsidiary, focusing on lending activities concentrated in real estate collateralized loans in New Jersey. The company’s financial statements consolidate the holding company, bank, and investment subsidiary, prepared under U.S. GAAP. The loan portfolio includes residential and commercial real estate loans, commercial and industrial loans, consumer loans, and specialized healthcare group loans. The securities portfolio includes mortgage-backed securities, government agency obligations, and corporate bonds. The company manages credit risk through an allowance for credit losses based on expected credit losses over the life of loans. The company completed its initial public offering in March 2026 as part of the conversion process.

Lifeward Ltd. designs, develops, and commercializes medical devices focused on physical rehabilitation and recovery. Its flagship products include the ReWalk Personal and Rehabilitation Exoskeletons for individuals with spinal cord injury, which enable ambulatory functions through motorized robotic legs. The company also markets the ReStore Exo-Suit for stroke rehabilitation and distributes MYOLYN MyoCycle FES Pro cycles. In 2023, Lifeward acquired AlterG, a provider of Anti-Gravity rehabilitation systems used globally. The company operates primarily in the U.S. and Europe, selling directly and through distributors. Lifeward has obtained FDA 510(k) clearances and European CE marks for its products and maintains compliance with quality management standards. It generates revenue from product sales, extended warranties, and repair services. The company has engaged in strategic transactions and capital raises to support growth and operations.

IB Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in Nevada, formed in 2020 and converted in 2023. Its business model is to identify and merge with or acquire a high-growth company, targeting sectors such as fintech, healthcare, life sciences, consumer goods, sports, and entertainment. The company targets businesses with enterprise values of at least $500 million and aims to provide a public vehicle for growth-oriented companies. The management team has extensive experience in investing, corporate finance, and restructuring, with a broad geographic network. The company has not selected a target prior to March 2026 but has entered into a business combination agreement with GNQ Insilico Inc., a Canadian AI-driven drug discovery company. The combination is subject to approvals and conditions, including maintaining minimum net tangible assets. The company’s financial position as of mid-2026 shows limited liquidity relative to liabilities, with a net loss reported for the quarter.

Hallmark Venture Group, Inc. is a smaller reporting company that functions as an intellectual property and licensing platform for drone technology. It holds worldwide rights to a portfolio of drone-related patents and trade secrets primarily registered in Korea. The company operates through joint ventures and co-production arrangements, aiming to expand into U.S., European, Middle Eastern, and allied markets. Sundori Korea, a related party, is a key supplier and service provider, holding exclusive rights to the technology within Korea. The company has no commercial operations or revenue and has reported losses with liquidity challenges. Its business model includes multiple revenue streams such as royalties, component sales, joint venture dividends, software fees, and technology transfer payments. The company faces regulatory, operational, and financial risks inherent in early-stage technology ventures and defense-related markets [S1][S2].

TOMI Environmental Solutions, Inc. operates in the environmental solutions sector, focusing on disinfection and decontamination products. The company has reported recent quarterly losses but maintains some liquidity with current assets exceeding current liabilities. It is engaged in a proposed merger with Carbonium Core, which is subject to financing and regulatory approvals. The company faces Nasdaq listing compliance challenges that may impact its stock liquidity and market presence.

PMGC Holdings Inc. is a diversified holding company managing four wholly owned subsidiaries as of December 31, 2025. These subsidiaries operate in medical aesthetics, biopharmaceuticals, investment, specialty packaging, and precision manufacturing sectors. Northstrive Biosciences focuses on developing engineered probiotic therapeutics for obesity-related muscle preservation, with lead asset EL-22 having completed Phase 1 clinical trials. PMGC Capital LLC is a multi-strategy investment firm targeting undervalued assets. Pacific Sun Packaging provides custom-engineered protective packaging solutions for sensitive IT hardware components, serving over 300 customers across semiconductor, data center, and networking supply chains. AGA Precision Systems specializes in high-tolerance CNC machining of complex metals for aerospace, defense, and industrial clients. The company has divested prior skincare operations to focus on biotechnology and acquisitions. Recent acquisitions include SVM Machining, AGA Precision Systems, and Pacific Sun Packaging, enhancing manufacturing and packaging capabilities. The company has utilized a $20 million equity facility to support growth initiatives and announced a long-term agreement with a Tier 1 firm through a subsidiary.

WinVest Acquisition Corp. is a Delaware-formed blank check company (SPAC) established in 2021 to effect a business combination with one or more target businesses. It completed its IPO in September 2021, raising gross proceeds of approximately $116 million including private placements, which were placed in a Trust Account. The company’s management team and advisory board have experience in digital financial services, acquisitions, and technology, aiming to identify and complete a successful business combination. The company initially targeted a digital financial media and investing platform but expanded its search to any industry or sector. It has no substantive commercial operations until completing its Initial Business Combination. The company has extended its deadline for completing the business combination multiple times, with the latest extension to April 17, 2025. It terminated a proposed combination with Xtribe during fiscal 2025. As of June 30, 2026, the company has very limited liquidity and reported a net loss for the quarter. The company retains broad discretion in evaluating and structuring its business combination, including due diligence and financial considerations [S1][S2][N8].

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing novel therapies targeting G-protein-coupled receptors (GPCRs) for obesity, overweight, and metabolic disorders. Its lead candidate, nimacimab, is a humanized IgG4 antibody that acts as a negative allosteric modulator and inverse agonist of the cannabinoid receptor 1 (CB1), designed to inhibit CB1 activity peripherally without crossing the blood-brain barrier. The company acquired nimacimab through the acquisition of Bird Rock Bio in August 2023. Nimacimab aims to provide an alternative or complementary approach to existing incretin-based therapies by preserving lean mass, increasing energy expenditure, and improving insulin sensitivity. Preclinical studies demonstrated dose-dependent weight loss and metabolic benefits in transgenic mouse models, while non-human primate studies showed a favorable safety profile with minimal CNS exposure. The company is advancing nimacimab through clinical development, including combination studies with GLP-1 agonists, and exploring additional metabolic indications. Skye Bioscience also announced a strategic combination with Redx Pharma to operate as Fibrx Therapeutics. Financially, the company reported a net loss and held approximately $8 million in cash and equivalents as of mid-2026. The company faces risks related to Nasdaq listing compliance, clinical development outcomes, and transaction completion.

APPYEA, INC is a technology company that historically focused on digital health solutions for sleep apnea and snoring using AI and sensing technologies. In 2025, the company pivoted to develop and operate a blockchain-based lottery and gaming platform. This platform leverages blockchain infrastructure, smart contracts, and verifiable randomness to enhance transparency, fairness, and regulatory compliance in lottery operations. The company offers a modular platform architecture supporting lottery lifecycle management, operator tools, and player engagement features. Commercial operations are in an early stage with one active customer deployment. The company generates revenue through setup fees, recurring service fees, and performance-based components.

Skyline Bankshares, Inc. operates as a bank holding company with its wholly-owned subsidiary, Skyline National Bank, providing retail and commercial banking services. The company has grown through mergers and acquisitions, including the 2024 acquisition of Johnson County Bank, which expanded its geographic footprint into Eastern Tennessee. The Bank's lending activities focus on real estate loans, which constitute the majority of its interest earning assets, along with commercial, agricultural, and consumer loans. The Bank manages credit risk through conservative loan-to-value ratios and thorough credit evaluations. Deposits, primarily core deposits, fund lending and investment activities. The Bank operates 28 full-service branches and two loan production offices across multiple counties in Virginia, North Carolina, and Tennessee. The company faces strong competition from a variety of financial institutions and fintech firms. It is regulated by the Federal Reserve, OCC, FDIC, and state authorities, complying with capital and operational standards. The company maintains an internet site providing investor relations information.

Mills Music Trust was established in 1964 to receive contingent purchase price payments related to a music and lyric copyright catalogue originally owned by Mills Music, Inc. The Trust receives quarterly payments from EMI Mills Music Inc., the current owner of the catalogue, which are based on royalty income generated by the catalogue. The Trust itself does not own copyrights or manage royalty collection; these responsibilities lie with EMI, administered by Sony/ATV Music Publishing LLC. The Trust distributes all net proceeds to unit holders and does not engage in other business activities. The catalogue includes over 12,000 titles, with a subset generating royalty income, primarily from songs with copyrights dating back to the early to mid-20th century. The Trust's financial reporting is limited to cash transactions without accrual accounting or balance sheet presentation.

CN Healthy Food Tech Group Corp. is a holding company operating through subsidiaries in China, specializing in health and wellness food products that blend modern technology with traditional Chinese medicine. The company’s product portfolio includes natural grain-based foods and supplements such as porridge, essential oils, and gummy supplements. Revenue is derived mainly from wholesale distribution to a network of distributors and live-stream sales of digital coupons redeemable at third-party merchants. The company acts as principal in these transactions, bearing inventory risk and controlling pricing. Marketing strategies employ a mix of digital and offline channels to attract and retain distributors and customers. The company relies on OEM suppliers for manufacturing, exposing it to supply chain risks. Financially, as of mid-2026, the company reported quarterly revenue of approximately $8.7 million and net income of $3.1 million, with solid liquidity metrics. However, the company’s securities have been halted from trading on Nasdaq since October 2025 due to regulatory review by the China Securities Regulatory Commission (CSRC), and it faces a delisting determination with an ongoing appeal. The CSRC imposed fines related to offshore listing filing procedures, which have been paid. The company also has defaulted promissory notes with potential dilution implications. These factors contribute to operational and regulatory risks.